Impact of long‑term elosulfase alfa treatment on clinical and patient‑reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England
Contact us t. +44 (0) 345 260 1087 e. firstname.lastname@example.org
MPS House Repton Place, White Lion Road Amersham, Buckinghamshire, HP7 9LP
MPS Commercial is a Private Limited Company Registered No 08621283. MPS Commercial trades as Rare Disease Research Partners and is a wholly owned, not for profit subsidiary of the Society for Mucopolysaccharide Diseases (the MPS Society), Registered Charity in England and Wales No 1143472. Rare Disease Research Partners social objectives are to reinvest any surplus to support the mission of the MPS Society to transform the lives of patients through specialist knowledge, support, advocacy and research.